
Friday, January 06, 2023 10:03:36 AM
Avail Scientific will be focusing its efforts on neurological data acquisition, data analysis, and data management with the explicit goal of better understanding and improving patient outcomes in multiple neurological disorders, with an initial focus on mental health and addiction.
Avail Scientific is continuing to establish key partners in the psychedelic medicine space to monitor the effectiveness and efficacy of Psychedelic medicines in mental health treatment as these modalities continue to demonstrate heightened effectiveness and gain regulatory acceptance.
Avail Scientific has been evaluating several promising ventures with research organizations and manufacturing laboratories for some time and expects to conclude several business partnerships in the near-term.
Avail Scientific's mandate is to support neurological, psychedelic and other medical research and treatments through neurological testing, data analytics and data management.
https://www.marketwatch.com/press-release/mobile-ladsavail-scientific-to-enter-the-neurological-testing-and-data-management-area-with-a-continued-emphasis-on-monitoring-the-effectiveness-of-psychedelic-medicines-in-mental-health-treatment-via-software-and-hardware-systems-2023-01-06?mod=mw_quote_news_seemore
FEATURED Cannabix Technologies Receives Notice of Allowance from USPTO for Contactless Breath Analysis • Jun 17, 2025 8:00 AM
Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies • AVAI • Jun 17, 2025 8:00 AM
A.R.T. Digital Holdings (OTC: CGAC) Secures Non-Dilutive Financing for George West Site Supporting NASDAQ: BTBT • CGAC • Jun 17, 2025 5:07 AM
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals • VAYK • Jun 11, 2025 9:45 AM
ECGI Holdings Invests in AI-Powered Fantasy Sports Startup Payday Fantasy • ECGI • Jun 10, 2025 8:30 AM
Avant Technologies Signs Letter of Intent for a Business Combination • AVAI • Jun 10, 2025 8:00 AM